GLP-1 receptor agonist – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:23 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg GLP-1 receptor agonist – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Dulaglutide Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-dulaglutide-market-2021-2025/ Fri, 21 May 2021 06:26:51 +0000 https://www.cri-report.com/?post_type=product&p=11424 Description Dulaglutide is a weekly long-acting GLP-1 receptor agonist developed by Eli Lilly and was approved to enter China in 2019. Dulaglutide is suitable for the blood glucose control of adult patients with type 2 diabetes, including single-drug and patients with poor blood glucose control after receiving metformin and/or sulfonylureas. By 2020, Eli Lilly Nederland BV is the only manufacturer in the Chinese Dulaglutide market. According to CRI’s market research, after Dulaglutide entered the Chinese market, the sales increased rapidly from CNY0.61 million in 2019 to CNY 10.37million in 2020.…

The post Investigation Report on China’s Dulaglutide Market 2021-2025 first appeared on CRI Report.

]]> Description
Dulaglutide is a weekly long-acting GLP-1 receptor agonist developed by Eli Lilly and was approved to enter China in 2019. Dulaglutide is suitable for the blood glucose control of adult patients with type 2 diabetes, including single-drug and patients with poor blood glucose control after receiving metformin and/or sulfonylureas. By 2020, Eli Lilly Nederland BV is the only manufacturer in the Chinese Dulaglutide market.

According to CRI’s market research, after Dulaglutide entered the Chinese market, the sales increased rapidly from CNY0.61 million in 2019 to CNY 10.37million in 2020. The annual growth rate is approximately 1601.52%.

CRI analyzes that the sales of Dulaglutide will keep a growth trend from 2021 to 2025 due to price reduction. At the end of 2020, the negotiation of Dulaglutide medical insurance was successful. The price for 1.5mg/0.5ml Dulaglutide injection was adjusted from CNY420 to CNY149. With the implementation of the latest price, the sales volume of Dulaglutide will increase, which will lead revenue to grow. Besides, the huge patient population will also continue to expand the Dulaglutide market. In China, on average, one in ten adults has diabetes, and 90% of diabetics are Type 2 diabetes. A large number of patients increases the demand for Dulaglutide. Moreover, Dulaglutide is clinically more effective and safer compared to other GLP-1 products. Thus, the share of Dulaglutide expands in the GLP-1 product market, thereby increasing its sales.

Topics Covered:
-The impact of COVID-19 on China’s Dulaglutide market
– Sales value of China’s Dulaglutide 2016-2020
– Competitive landscape of China’s Dulaglutide market
– Prices of Dulaglutide in China
– Prices of Dulaglutide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dulaglutide market
– Prospect of China’s Dulaglutide market from 2021 to 2025

The post Investigation Report on China’s Dulaglutide Market 2021-2025 first appeared on CRI Report.

]]>